Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 368
7
Diseases
5
Unique genes
0.364
Avg. similarity score
Chronic progressive external ophthalmoplegia
Most-connected disease (5 links)
Disease
Searched: Progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal recessive 2
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal recessive 2
Chronic progressive external ophthalmoplegia
Mitochondrial dna depletion syndrome 8a (encephalomyopathic type with renal tubulopathy)
Progressive external ophthalmoplegia with mitochondrial dna deletions (autosomal dominant)
Progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant, 5
Rod-cone dystrophy, sensorineural deafness, and fanconi-type renal dysfunction
Camptocormia
Member diseases (most connected first ‐ the cluster's core)
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| RRM2B | 6 / 7 | Camptocormia, Chronic progressive external ophthalmoplegia, Mitochondrial dna depletion syndrome 8a (encephalomyopathic type with renal tubulopathy), Progressive external ophthalmoplegia with mitochondrial dna deletions (autosomal dominant) and 2 more |
| RNASEH1 | 2 / 7 | Chronic progressive external ophthalmoplegia, Progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal recessive 2 |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
None of these pathways reaches significance (all FDR q ≥ 0.05). They’re the best candidates found, but treat them as weak evidence for why this cluster groups together.
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Interconversion of nucleotide di- and triphosphates | Reactome | 1 / 29 | 82.8× | 1.20e-2 | 6.35e-2 |
| DNA replication | KEGG | 1 / 36 | 66.7× | 1.49e-2 | 7.22e-2 |
| Base excision repair | KEGG | 1 / 44 | 54.6× | 1.82e-2 | 8.12e-2 |
| Pyrimidine metabolism | KEGG | 1 / 58 | 41.4× | 2.39e-2 | 9.49e-2 |
| Glutathione metabolism | KEGG | 1 / 59 | 40.7× | 2.43e-2 | 9.60e-2 |
| Viral myocarditis | KEGG | 1 / 70 | 34.3× | 2.88e-2 | 1.06e-1 |
| p53 signaling pathway | KEGG | 1 / 75 | 32.0× | 3.08e-2 | 1.10e-1 |
| Drug metabolism - other enzymes | KEGG | 1 / 81 | 29.7× | 3.33e-2 | 1.15e-1 |
| Nucleotide metabolism | KEGG | 1 / 85 | 28.3× | 3.49e-2 | 1.18e-1 |
| TP53 Regulates Metabolic Genes | Reactome | 1 / 86 | 27.9× | 3.53e-2 | 1.19e-1 |
| Cardiac muscle contraction | KEGG | 1 / 87 | 27.6× | 3.57e-2 | 1.19e-1 |
| Hypertrophic cardiomyopathy | KEGG | 1 / 99 | 24.3× | 4.05e-2 | 1.28e-1 |
| Dilated cardiomyopathy | KEGG | 1 / 105 | 22.9× | 4.30e-2 | 1.33e-1 |
| Thyroid hormone signaling pathway | KEGG | 1 / 122 | 19.7× | 4.98e-2 | 1.44e-1 |
| Purine metabolism | KEGG | 1 / 128 | 18.8× | 5.22e-2 | 1.48e-1 |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| mitochondrial DNA replication | GO:0006264 | 2 / 11 | 680× | 3.15e-6 | 2.18e-4 ✓ sig. |
| deoxyribonucleoside triphosphate metabolic process | GO:0009200 | 1 / 1 | 3,737× | 2.68e-4 | 6.25e-3 ✓ sig. |
| regulation of slow-twitch skeletal muscle fiber contraction | GO:0031449 | 1 / 2 | 1,869× | 5.35e-4 | 9.88e-3 ✓ sig. |
| ribonucleoside diphosphate metabolic process | GO:0009185 | 1 / 3 | 1,246× | 8.03e-4 | 1.28e-2 ✓ sig. |
| deoxyribonucleotide biosynthetic process | GO:0009263 | 1 / 3 | 1,246× | 8.03e-4 | 1.28e-2 ✓ sig. |
| 2'-deoxyribonucleotide biosynthetic process | GO:0009265 | 1 / 3 | 1,246× | 8.03e-4 | 1.28e-2 ✓ sig. |
| regulation of cell fate commitment | GO:0010453 | 1 / 3 | 1,246× | 8.03e-4 | 1.28e-2 ✓ sig. |
| regulation of the force of skeletal muscle contraction | GO:0014728 | 1 / 3 | 1,246× | 8.03e-4 | 1.28e-2 ✓ sig. |
| DNA replication proofreading | GO:0045004 | 1 / 3 | 1,246× | 8.03e-4 | 1.28e-2 ✓ sig. |
| negative regulation of epidermal cell differentiation | GO:0045605 | 1 / 3 | 1,246× | 8.03e-4 | 1.28e-2 ✓ sig. |
| DNA replication, removal of RNA primer | GO:0043137 | 1 / 4 | 934× | 1.07e-3 | 1.51e-2 ✓ sig. |
| formation of anatomical boundary | GO:0048859 | 1 / 4 | 934× | 1.07e-3 | 1.51e-2 ✓ sig. |
| positive regulation of G0 to G1 transition | GO:0070318 | 1 / 5 | 747× | 1.34e-3 | 1.71e-2 ✓ sig. |
| regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | GO:0090092 | 1 / 6 | 623× | 1.60e-3 | 1.88e-2 ✓ sig. |
| positive regulation of mitotic cell cycle phase transition | GO:1901992 | 1 / 7 | 534× | 1.87e-3 | 2.05e-2 ✓ sig. |